1️⃣ Who attends (BUYERS / ATTENDEES)

SIOP congresses are typically not consumer-facing; they are specialist events where the “buyer” population is mostly formed by decision-makers and highly influential stakeholders in clinical, academic, and research settings. Based on the congress’s stated mission and positioning (“worldwide community… improve outcomes for every child facing cancer”), the most relevant buyer-attendee groups generally include:

Primary buyer/decision-maker attendee clusters

• Paediatric oncology clinicians and department leaders (high influence over treatment standards, adoption of therapies, and protocol engagement)
• Academic researchers and translational science leaders (influence on research collaborations, study design, and platform choices)
• Clinical trial operations leadership (study feasibility support, vendor selection influence, CRO/central lab relationships)
• Haematology/oncology and supportive care specialists (strong relevance for supportive interventions, symptom management, survivorship care)
• Medical affairs & evidence generation stakeholders (speaker programs, scientific symposia, and data-driven partner discussions)
• Regulatory/medical information and access stakeholders (particularly relevant for global launches and evidence packages)
• Institutional leadership (hospital network administrators, program directors, research institute managers)
• Industry science/partnership teams (business development, partnerships, and strategic alliances—often “buyers” in practice)

Buyer fit logic: SIOP is purpose-built for paediatric/adolescent oncology. That means buyers with products and services aligned to therapies, diagnostics, clinical research enablement, or patient-support ecosystems are naturally present and engaged.

Secondary attendee groups that still matter commercially

• Young investigators, fellows, and trainees (high network value; can influence future research directions)
• Allied health professionals in paediatric oncology care pathways (nursing leadership, survivorship care coordinators)
• Associations and society-linked professionals (often connect industry to investigator networks)

2️⃣ Where the show is happening + attendee geographic origin

The official text confirms the congress is in San Antonio, Texas, USA from September 15–18, 2026. It does not specify the venue name in the provided excerpt, so we only lock the city and country.

Geographic origin (what we can reliably infer)

The congress is described as a worldwide and global multidisciplinary society devoted to paediatric and adolescent cancer. While the provided content does not list attendee countries, the logical attendee origin pattern for a global society congress is: strong international participation plus substantial North American presence (given the US location and North America relevance).

Best geographic targeting for outreach

• North America: United States and Canada (high likelihood due to location and clinical research density)
• Europe: United Kingdom, Germany, France, Italy, Spain, Netherlands, Scandinavia (high participation in oncology networks)
• Asia-Pacific: Japan, China, South Korea, Australia, Singapore (common for global medical congress attendance)
• Latin America: Brazil and Mexico (often active in international oncology collaborations)
• Middle East & Africa: targeted centers with paediatric oncology programs (selective but valuable)

If we receive the client’s ideal markets (e.g., US-only vs. global), we can tighten the targeting strategy further.

3️⃣ Audience reach (Local / National / Global)

Reach type: Global.

The event is hosted by a worldwide multidisciplinary society focused on paediatric and adolescent cancer. Even though it is held in the United States, it is positioned as a worldwide community and a global scientific meeting.

• Local/National component: Strong US oncology and academic presence
• Global component: International clinical and research attendance typical of major global oncology society congresses

4️⃣ Sample buyer company names (BUYERS ONLY) + Websites

Below is a practical buyer list starter set for outreach and deeper research. These are buyer-style organizations that commonly participate in paediatric oncology ecosystems through therapies, diagnostics, clinical trial enablement, or supportive care innovations. (Names and websites are provided for candidate building; final qualification should be based on the client’s exact product category and ICP fit.)

Top 5 best buyer samples to send first (highest relevance starting set)

Note: We purposely included only buyer-relevant organizations and recommended validation for any edge cases. Final prioritization should be driven by the client’s product category (therapeutic, device, diagnostics, trial services, digital solution, etc.).

5️⃣ Job profiles, industries & event type

Best job profiles to target

• Medical Affairs Director / Medical Science Liaison (MSL) Lead (evidence, scientific programming alignment, access discussions)
• Clinical Development / Clinical Operations Director (trial enablement, protocol and study planning)
• Global Program Lead, Oncology (cross-functional decision influence for trials and partnerships)
• Translational Research Lead / Biomarker Strategy Lead (strong fit for genomics and targeted research)
• Diagnostics / Companion Diagnostics Product Manager (if relevant to the client offering)
• Scientific Partnerships / Business Development Director (collaborations and investigator networks)
• Clinical Trial Solutions Director (CRO/analytics providers) (feasibility and execution capabilities)
• Regulatory Strategy Director (evidence packages and clinical documentation planning)
• Oncology Imaging Solutions Lead (if the client supports imaging/assessment workflows)
• Supportive Care / Patient Support Program Leadership (if the client focuses on survivorship, adherence, or patient services)

Industries that align strongly

• Pharmaceuticals
• Medical Devices
• Hospital & Health Care (where academic medical centers operate)
• Biotechnology
• Research and Scientific/clinical services (often represented across multiple supplier categories)
• Computer Software and Information Technology & Services (only when the client product is digital health, data platforms, or trial tech)
• Outsourcing/Offshoring (for CROs, trial operations, or specialized clinical services)

Event type

Scientific & medical conference with a strong emphasis on paediatric and adolescent oncology research, clinical advancement, and multidisciplinary collaboration. It also includes networking via congress programming and associated symposia/pre-congress activities (the provided text references an “SIOP NEXT Symposium” and a North America pre-congress, but does not include further operational detail in the excerpt).

6️⃣ Estimated attendance (expected total footfall)

The provided official excerpt includes date and location, but it does not provide an estimated attendance figure. Therefore, we are leaving the attendance estimate blank based on the instruction to avoid unreliable assumptions.

Estimated total attendance: (not specified in provided official text)

7️⃣ Key focus areas & buyer engagement

The official description emphasizes multiple buyer-relevant priorities: cutting-edge science, engaging debates, and networking with world renowned experts to improve outcomes for children facing cancer.

Key focus areas (how buyers align)

• Clinical science in paediatric oncology (treatment advances, trial outcomes, standard-of-care discussions)
• Translational and biomarker research (moving research into clinical impact)
• Collaborative multidisciplinary care models (multidisciplinary debates and practice evolution)
• Network-building across global paediatric oncology communities (partnerships, investigator connections)
• Ongoing education and career development (advancing paediatric oncology careers is explicitly mentioned)

Buyer engagement themes

• Evidence & outcomes narrative: Buyers will prioritize data-backed impact and practical relevance to paediatric and adolescent cancer care.
• Trial and research enablement: CRO/diagnostics/lab services and clinical trial technology stakeholders engage around feasibility, endpoints, and operational needs.
• Partnership pathways: Business development, scientific partnerships, and medical affairs teams typically engage around collaboration opportunities.

Best “engagement angle” we should use

We position outreach around reaching paediatric oncology medical decision-makers and research leaders who actively influence clinical research direction, adoption of innovations, and collaboration partnerships.

8️⃣ Client-product fit validation (requires client website)

To identify the best buyer profiles for this event based on the client’s specific offering, we need the client website (or product category page). The provided instructions indicate we should review the client’s website and then refine buyer targeting.

Client website: (not provided in the request)

Best buyer segments (provisional, pending client review):

• Medical Affairs leadership in oncology (for therapies, supportive care, or medical evidence platforms)
• Clinical Development / Clinical Operations decision-makers (for trial services, central lab/diagnostics, clinical tech)
• Translational Research & Biomarker Strategy leaders (for genomics, diagnostics, research tools)
• Scientific Partnerships / BD teams (for consortiums, investigator networks, co-development)

Please share the client website so we can update this section with an accurate, product-led buyer shortlist.

Also: industry selection guidance (from the event fit perspective)

Until we have the client product review, we recommend focusing industries that map to the paediatric oncology ecosystem: Pharmaceuticals, Biotechnology, Medical Devices, Hospital & Health Care, Research, and (if applicable) Computer Software / Information Technology & Services.

9️⃣ Final recommendation (buyer qualification scorecard)

Overall event suitability: High for buyers aligned to paediatric and adolescent oncology. SIOP 2026’s global specialty focus creates a strong match for targeted outreach—especially for organizations involved in therapies, diagnostics/biomarkers, clinical development enablement, trial services, imaging/assessment solutions, and supportive care ecosystems.

Best buyer segments to prioritize (actionable shortlist)

• Oncology Medical Affairs Directors / Medical Strategy leaders
• Clinical Development & Clinical Operations Directors
• Translational Research & Biomarker Strategy Leads
• CRO/trial solutions leadership
• Diagnostics or companion diagnostics product leadership (if applicable)
• Scientific Partnerships & BD leadership

What we need from the client to finalize an “ideal buyer list”

• Client website URL (required)
• Product category (therapy/device/diagnostics/digital/trial services/patient support)
• Target geography (US-only vs global)
• Deal type (distribution, partnerships, clinical trials, institutional adoption, etc.)